Head and neck squamous cell carcinoma (HNSCC) are a heterogeneous group of cancers 16 affecting multiple subsites, including oral cavity. Oral or anterior tongue tumors (OTSCC) are an 17 aggressive group of squamous cell carcinomas, characterized by their early spread to lymph nodes 18 and higher rate of regional failure compared to other oral cavity cancers. There is a rise in the 19 incidence of oral tongue cancer among younger population (<50yrs); many of who lack the typical 20 associated risk factors of alcohol and/or tobacco exposure. In order to carry out an ensemble 21 learning and prediction method with multiple parameters classifying survival, we generated data, on 22 somatic mutations in genes from exome sequencing, immediate upstream and downstream flanking 23 nucleotides of the somatic mutations, DNA methylation, loss of heterozygosity (LOH), copy 24 number variations (CNV), gene expression, significant pathways altered and Human Papilloma 25 Virus (HPV) infection, from 50 OTSCC patients. Results of our analysis identified somatic 26 mutations in NOTCH2 and/or TP53, and/or LOH in 11p to associate with better disease free 27 survival in HPV positive patients (P = 0.0254) and not in HPV negative patients (P = 0.414). We 28 validated the latter in patients without HPV infection from TCGA cohort (P = 0.369, N = 17 for 29 2 TCGA_ OralTongue; P = 0.472, N = 67 for all TCGA_HNSCC patients). Integrated analysis, 30 including pathways, linked survival with apoptosis and aberrant methylation in SLC38A8 (P = 31 0.0129). 32 33 Author Summary 34 Oral tongue squamous cell carcinomas (OTSCC) are a homogenous group of head and neck 35 tumors characterized with aggressive behavior among younger patients. In this report, we have 36 analysed genetic variants, expression and DNA methylation changes across 50 oral tongue primary 37 tumors along with the Human Papilloma Virus (HPV) infection status in those tumors to identify 38 factors associated with disease free survival. Our data identified somatic mutations in the genes 39 NOTCH2, TP53 and LOH in 11p, to be significantly associated with better disease free survival in 40 HPV positive patients (P = 0.0254), but not in HPV negative patients (P = 0.414). We validated the 41 latter using patients without HPV infection from TCGA (P = 0.369, N = 17 for 42 TCGA_OralTongue; P = 0.472, N = 67 for all TCGA_HNSCC patients). Integrated analysis linked 43 survival with apoptosis and aberrant methylation in SLC38A8 (P = 0.0129).
Introduction 46
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of malignancies 47 with different incidences, mortalities and prognosis for different subsites and are the sixth leading sensitivity (number of accurate predictions) and Spec -specificity (classes of accurate predictors). 134 We penalized the score based on repC, and reward for the latter three components. 135 136 We found patient-specific survival signatures for various predictor categories 137 ( Supplementary Table 3 ), which included candidate markers known to be associated with survival, 138 like TP53 and NOTCH2 genes, and LOH in 11p [34] [35] [36] . We conducted a number of single-139 parameter analyses and a combined-parameter one, which included the top scoring predictors from 140 all the single-parameter analyses.
142
Non-parametric tests predicted the overall prediction score to be highest for the somatic 143 mutation predictor for all DFS categories (Fig. 1A ). In the low DFS category, the 3' nucleotide 144 flanks ranked second in predicting poor survival with a high score. Overall survival prediction score 145 was also highest with the mutation category predictor for low and high DFS categories, except for 146 the med category, where the somatic mutations ranked first ( Supplementary Fig. 1 ). Following 147 overall analysis, we compared the individual components of the prediction score, and found repE to 148 contribute largely to the overall score for somatic mutation category frequencies (Fig. 1B) . Sensitivity was highest for combined, methylation and pathways, while the former two also 151 had the largest specificity. A similar trend was observed with overall survival as well 152 ( Supplementary Fig. 1 ). We estimated the error in survival prediction using the 0.632+ 153 bootstrapping method [18] . The errors varied across the low, med and high categories of disease-154 free survival ( Supplementary Fig. 2A ). The median error was low (<0.3) for the low category for all 155 single-parameter analyses, but was relatively higher (~0.75) for the combined-parameter analyses. 156 The med and high categories had the least median errors (~0.25) for the combined-parameter 157 analyses. 158 159 In order to test the specificity of the survival predictors in the OTSCC study, we performed 160 cross-validation using somatic mutation data from three different cancer types (TCGA), either 161 individually or combined. These cancer types were selected based on certain inclusion criteria (see 162 Methods). We found that the survival predictors identified were specific to OTSCC cancer type, 163 against any of the three cancer types, tested individually or pooled ( Supplementary Fig. 2B ).
165
For Kaplan-Meier cumulative survival probability analyses on combinations of parameters, 166 we picked TP53 and NOTCH2, and 11p, from gene-and LOH-based single-parameter analysis, 167 respectively. We then assessed survival probability in HPV-background, both in OTSCC and 168 TCGA_HNSCC datasets. However, due to the lack of sufficient number of HPV-positive samples 169 in any of the TCGA_HNSCC subsites, we could only perform survival probability analyses using 170 the OTSCC dataset. The number of samples used for survival probability analyses for various 171 datasets and the exact locations of TP53 and NOTCH2 mutations in the internal OTSCC dataset are 172 provided in Supplementary Table 4 .
174
We observed that HPV-positive OTSCC patients, who harbor at least one somatic mutation 175 either in TP53 or NOTCH2, or LOH in 11p, have better disease-free survival (P = 0.0254; Fig. 2A ).
176
The same is not observed, however, for HPV-negative OTSCC patients (P = 0.414; Fig. 2B ). We 177 also found that presence of HPV DNA in tumors or somatic mutations/changes in these genes alone The TCGA_OralTongue dataset had only one HPV-positive sample (out of 90, where DFS 181 data are available), which harbored a TP53 mutation but was wild type for NOTCH2 and 11p, and 182 among all other TCGA_HNSCC HPV-positive samples (N = 37), 13 patient tumors harbor 183 mutations in TP53 and/or NOTCH2 and/or LOH in 11p. However, since these samples were 184 sparsely distributed across multiple sub-sites with different biology and HPV infection rates known 185 to affect survival to varying degrees (for example, a clear link between HPV and survival in 186 oropharyngeal tumors verses no clear data on oral cavity tumors), we did not pool all the HPV-187 positive patients from the TCGA cohort for analyses. We, however, validated our findings in 188 patients without HPV infection using three other sets of samples from TCGA (P = 0.369, 0.723 and 189 0.472; Fig. 3A 198 199 In order to determine a minimal predictor set for survival in OTSCC patients, we performed 200 integrated analysis with all predictors in OTSCC patients. We included 120 genes bearing somatic Supplementary Table 3 ). For further detailed Kaplan-Meier cumulative survival 205 probability analyses on combinations of parameters, in addition to methylation in SLC38A8 and 206 nucleotide flanks, we picked TP53 and NOTCH2 from the gene-based survival prediction analyses, 207 the former also affecting the apoptosis pathway, along with LOH in the 11p arm, the highest repE-208 scoring single-parameter analyses and also a known correlate of survival. As shown in Fig. 4 , 209 apoptosis pathway, CpG island methylation of the SLC38A8, somatic mutations in TP53, NOTCH2 210 and/or LOH in 11p, forms a minimal predictor for survival in HPV infected OTSCC patients (P = 211 0.0129; Fig. 4A ), but not in patients not infected with HPV (P = 0.772; Fig. 4B ). We could not 212 validate the results from the combined parameter analyses with the TCGA data, as we did not have 213 both the whole-genome 450K DNA methylation data and raw sequence files to extract the flanking 214 nucleotide information for the same tumors. that HPV plays a limited role outside the oropharynx. In the current study, we investigated the 227 contribution of multiple parameters from genome-wide studies, somatic mutations, indels, 228 immediate flanking nucleotides of somatic mutations, genes and pathways affected by somatic 229 mutations and indels, DNA methylation, LOH, and HPV on disease free survival in patients with 230 oral tongue tumors using a statistical machine learning approach. Synonymous mutations have 231 often, with some evidence, been thought to exert an effect on the function of the gene [39]. For 232 example, a recent report reveals the possibility that many of the synonymous mutations can act as 233 driver mutations in some cancers [40] . We therefore, included them in our analyses. Neighboring nucleotide biases have been reported in various studies previously [22] [23] [24] [25] and 236 were linked to a wide range of properties [26] [27] [28] [29] . Sequence context plays an important role in 237 cancer [29] [30] [31] [32] . For example, guanine holes are linked to pathogenic cancer-specific mutations [41] .
238
In fact, cancer-type specific mutation signatures with the context of flanking residues have been 239 identified in many cancers [42] . Therefore, we wanted to study the effect of neighboring nucleotides 240 of somatic mutations on survival as an independent predictor, and in combinations with other 241 parameters. In our study, the overlap between annotations from genomic locations of somatic 242 mutations, and the genes and pathways that harbor them provides independent functional validation 243 of the predicted locations and their neighborhood. The contribution of different parameters in three 244 groups of patients was different. In patients with median DFS of <1yr, the contribution of somatic 245 mutations alone was highest but in patients with median DFS >2yrs, it was both the somatic 246 mutations and LOH that contributed near equally (Fig. 1 ). The overall best prediction of survival 247 suggests that both somatic mutations and LOH are the best predictors ( Fig. 2 ). We found that the 248 flanking nucleotides was a contributing factor and it is possible that the effect of positional context 249 outweighs that of functional context, looking at the lower prediction scores of gene and pathway-250 based models in comparison to all genomic locations of somatic mutations (133 for genes, 18 for 251 pathways and 3400 for somatic mutations; Supplementary Table 3 ). The relatively low error for the 252 'low' survival category for all single-parameter analyses, and for the 'med' and high' categories for 253 all combined-parameter analyses highlights the predictive scope of the two kinds of analyses 254 ( Supplementary Figure 2A) . 255 256 HPV acts through its oncoproteins E6 and E7 that bind and inactivate the cellular tumor 257 suppressor p53 and the retinoblastoma gene product pRb respectively. The degradation of p53 is 258 mediated through ubiquitin pathway. Although HPV has been shown as a good prognostic marker 259 in oropharyngeal cancer, its role in oral cavity tumors is unclear. Past studies have attributed HPV 260 status with therapeutic response and survival in oropharynx tumors [43] [44] [45] . Recently, Fakhry et al.
261
(2014) showed that patients with oropharyngeal cancer who are p16-positive have significantly 262 improved survival rates when compared with the patients who are p16-negative [46] . Unlike 263 oropharynx, data on the role of HPV in oral cavity carcinomas, including oral tongue, is less 264 conclusive. Previous data showed that the number of patients infected with HPV is much higher in 265 the case of oropharyngeal cancers than those with oral cavity cancers in the United States [47] .
266
HPV prevalence in oral cavity tumors in the United States was shown to be very low (1.5%) [48] to 267 moderate (12.5%) [46] . A recent study in Europe showed 26% of HPV prevalence in oral tongue 268 tumors [45, 46] . Contrary to the data from the United States [48, 49] and closer to the HPV data 269 from Europe [50] , studies from India previously reported a high prevalence of HPV in oral cavity 270 tumors, including in oral tongue (anywhere between 18-51% depending on the HPV detection assay 271 used) [51, 52] . Although the reason(s) and importance for such a high prevalence of HPV in our 272 geography is currently not known, the association of HPV with well-differentiated squamous cell 273 carcinoma of oral cavity has been reported in the past [51] in contrast to the oropharyngeal tumors.
274
In a sample size of 50, we found that 38% of the patients were p16 positive and 46% of patients 275 were HPV positive, which is closer to the HPV data obtained earlier in Indian cohorts [51, 52] . A 276 larger sample size and HPV assays with higher sensitivity and specificity in the future will shed 277 more light on the prevalence of HPV in oral cavity tumors. Our results on LOH in 11p and its 278 relationship with survival might link HPV infection in some samples as deletion of 11p was 279 previously shown to enhance viral E6/E7 transcription and virus-mediated cellular transformation in 280 fibroblasts [53] . In our data, we did not find any significant relationship between survival and LOH 281 in 11p when the patients are not stratified based on HPV. It is also known that 11p harbors many In our study, we found 19% of the patients that harbor somatic mutations in TP53 are HPV 288 positive. Even if this was surprising owing to the fact that E6 blocks the function of p53 previous 289 HNSCC studies reported varying numbers of somatic TP53 mutations in HPV positive background 290 (16% ICGC India [6] and 6.1% TCGA [7] ). The reason behind why certain HPV +ve tumors bear 291 mutations in TP53 is currently unknown. One possibility is that HPV-positive TP53 mutant tumors 292 may represent a separate group of recurrent/metastatic tumors.
294
Given the absence of any large study involving patients with oral tongue tumors and the lack 295 of sensitivity of current assays employed to detect HPV, we believe that our data stands unique. As 296 studies involving large number of HPV infected patients in oral tongue are currently missing, we 297 could not validate our findings with a large number of patients. Since we used only patients with 298 confirmed HPV status in all tests involving HPV as a parameter, the effective number of patients 299 was low in all combinations that harbored somatic mutations in TP53, and/or, in NOTCH2 and/or, 300 LOH in 11p. This is one of the drawbacks of our current study. It is interesting to note that presence 301 or absence of HPV infection alone does not associate with better disease free survival (Fig. 2) . In 302 the larger cohort of HNSCC patients without HPV infection, TP53, NOTCH2 and 11p do not play a 303 role in impacting survival in head and neck tumors. These genes link with other important genes 304 and pathways shown to be important in HNSCC and their survival ( Supplementary Fig. 3 ). Our 305 study does not establish the mechanistic insights on why patients with tumors, that are positive in 306 HPV DNA and bear mutations in TP53 and/or NOTCH2, survive longer. This is especially so as it 307 is counter-intuitive to what is known about TP53 mutations and survival. However, a detailed study 308 on the relationship between mutations in TP53, NOTCH2 and HPV infection in HNSCC is currently 309 lacking, as there are not many tumors described in the literature that bear mutations in TP53 and/or 310 NOTCH2 and are positive for HPV DNA. Future studies will shed light on this. Kaplan-Meier 311 analyses using mutation data from other NOTCH receptors (NOTCH1, NOTCH2NL and NOTCH3) 312 did not result in a significant survival signature ( Supplementary Table 1 ), emphasizing the 313 importance of NOTCH2. In fact, NOTCH2 has been shown to act as a driver in HNSCC, previously 314 (Pickering et al. 2014) . Like our study, the other sequencing studies also have shown presence of 315 somatic mutations in NOTCH1 and NOTCH2 somatic mutations in oral cavity tumors to vary (13% 316 and 5% in [4] ; (13% and none in [5] ; 16% and none in [3] ; 18% and 6% in [6] and 3% and 1% in 317 the oral tongue subsites from a larger TCGA cohort [7] . The frequency of NOTCH1 and NOTCH2 318 non-synonymous mutations in our study is (4% each) is very similar to the oral cavity tumors in 319 some of the above studies. In our study, we used both synonymous and non-synonymous somatic 320 mutations for NOTCH1 and NOTCH2. When we did similar analyses with other NOTCH receptors 321 using TCGA data, the role of NOTCH2 becomes even clear for this cohort (Supplementary Table   322 1). Patient samples used in the study 331 Details of the blood, matched normal and tumor specimens collected and used in the study are 332 described elsewhere [33] . Only those patients with histologically confirmed squamous cell 333 carcinoma that had at least 70% tumor cells in the specimen were recruited for the study. Fifty Exome sequencing, whole-genome SNP microarray and methylation array 342 We generated data on somatic mutations and flanking nucleotides from exome sequencing,
343
DNA methylation using Illumina 450K microarrays, LOH and copy number variations using 344 Illumina Omni whole-genome 2.5million SNP microarrays from patients (N = 50) with OTSCC to 345 discover signature of survival. Details on cataloguing these variants and the computational pipeline 346 used for discovery of variants are described elsewhere [33] . Somatic variants were narrowed down 347 further to contain only those, which have no read coverage in the matched normal. These somatic 348 variants contained synonymous and non-synonymous mutations, frame-shifted and in frame 349 insertions and deletions. The pre-processed somatic variants for various cancer projects along with 350 the survival information for each patient were used for building models for survival prediction using 351 varSelRF, an R Bioconductor package encoding variable selection from random forests. Two out of 352 fifty patients were not included in further analyses, as they did not pass the study inclusion criteria.
354
Feature selection with flanking nucleotides around somatic mutations 355 We calculated somatic mutation frequencies after classifying them into six mutation categories, 356 and their +/-1 and +/-3 nucleotide flanking sequence neighborhood ( Supplementary Table 3 ). For 357 our study, we have used both the immediate single neighboring nucleotide (+/-1) and three Other random forest models for feature selection 373 In addition, we validated the results by building random forest models based on the actual 374 mutations including their genomic location information, their gene and pathway annotations, arm-375 level LOHs and probe-wise methylation differences. In all thus, we had eight random forest models 376 for variable selection. In the somatic mutations, genes and pathways models, we restricted the 377 somatic mutations to only those that have gene and pathway annotations and performed a set of 378 analyses where we did not restrict it to the gene and pathway information, for comparison. For 379 annotation, mutations were mapped using BEDTools version 2.16 on the ENSEMBL 75 database, 380 for genes, followed by pathway mapping using GraphiteWeb.
382
Variable selection 383 The algorithm performs both backward elimination of variables and selection based on the 384 importance spectrum. About 20% of the least important variables are eliminated iteratively until the 385 current OOB error rate becomes larger than the initial OOB error rate or the OOB error rate in the 386 previous iteration. We performed the above step with 500 iterations, each time with a different seed, 387 and recorded for each, the accuracy of survival prediction with the minimal set of parameters, along 388 with the set size, the actual identity of parameters. We further assessed the number of times a 389 minimal set was repeated over the 500 repetitions. We computed a metric by multiplying the 390 prediction accuracy (sensitivity and specificity) and repeatability, and dividing the product by the (predict(DS.rf.vsf$rf.model, subset(DS[, ds.rf$importance [-1,3] 419 #Importance values after FDR correction 420 p.adjust (ds.rf$importance[-1,3] , method = "BH", n = 6) 421 422 .632+ bootstrapping 423 In order to understand the specificity of the best minimalistic predictors of survival, we 424 estimated the .632+ error rate [18] over 50 bootstrap replicates, for each of our analysis. We used 425 the varSelRFBoot function from the varSelRF Bioconductor package to perform bootstrapping. The 426 .632+ method is described by the following formula:
where Err (.632+) , Err (.632) , Err (1) and err are errors estimated by the .632+ method, the original .632 430 method, leave-one-out bootstrap method and err represents the error. R represents a value between 431 0 and 1. Another popular error correction method used is leave-one-out bootstrap method [21] . The
432
.632+ method was designed to correct the upward bias in the leave-one-out and the downward bias Cross-validation using TCGA data 442 In order to infer the specificity of survival predictors for the OTSCC study, we performed 443 cross-validation, in addition to the .632+ bootstrapping approach using three different datasets from 444 TCGA (LUSC, GBM and SKCM). The cross-validation was performed while using the three 445 datasets either individually or after combining them. These three cancer types were chosen based on 446 the availability of DFS information, presence of approximately equal number of patients across low 447 (<=12 mo), med (12-24 mo) and high (>=24 mo) DFS categories, and presence of a total of at least 448 30 patient samples with whole exome sequencing data. We calculated the survival prediction score 449 based on four components: repC -number of repeatability (confidence) classes, repE -confidence 450 scores of predictors, Sen -sensitivity (number of accurate predictions) and Spec -specificity 451 (classes of accurate predictors). In order to penalize against too many predictors, we arrived at the We performed cross-validation for the random forest analyses using six mutation categories and 457 immediate 5' and 3' single nucleotide flanks. For these categories, TCGA data possessed the exact 458 same information as the OTSCC data. HPV infection status 465 We detect HPV positivity using quantitative and droplet digital PCR (ddPCR) assays as All scripts used to deriving data and infer conclusions are provided in Supplementary Scripts. 
